Protective effects of astaxanthin on 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells

Journal of Neurochemistry

Volumn 107, Issue 6, 2008, Pages 1730-1740

  Ikeda, Yasutaka ^a,b   Tsuji, Shinji ^c   Satoh, Akira ^c   Ishikura, Masaharu ^c   Shirasawa, Takuji ^a,b,d   Shimizu, Takahiko ^a,b,e  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b Anti Aging Science Inc   (Japan)

^c YAMAHA MOTOR CO   (Japan)

^d JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

6 hydroxydopamine; Astaxanthin; Neurotoxicity; p38 mitogen activated protein kinase; Parkinson's disease; Reactive oxygen species

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ASTAXANTHIN; CASPASE 3; CASPASE 9; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 9; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE 1;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUROBLASTOMA CELL; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADRENERGIC AGENTS; ANNEXIN A5; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CYTOCHROMES C; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REACTIVE OXYGEN SPECIES; XANTHOPHYLLS;

ANIMALIA;

EID: 56749107503     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05743.x     Document Type: Article

References (59)

1. Alam Z. I., Jenner A., Daniel S. E., Lees A. J., Cairns N., Marsden C. D., Jenner P. Halliwell B. (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69, 1196 1203.
2. Andrew R., Watson D. G., Best S. A., Midgley J. M., Wenlong H. Petty R. K. (1993) The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem. Res. 18, 1175 1177.
3. Blum D., Torch S., Lambeng N., Nissou M., Benabid A. L., Sadoul R. Verna J. M. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65, 135 172.
4. 2 on iron-dependent DNA strand breaks and related processes in the neuroblastoma cell line SK-N-SH. Cancer Res. 51, 6066 6072.
5. Cain K., Bratton S. B., Langlais C., Walker G., Brown D. G., Sun X. M. Cohen G. M. (2000) Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes. J. Biol. Chem. 275, 6067 6070.
6. Choi W. S., Yoon S. Y., Oh T. H., Choi E. J., O'Malley K. L. Oh Y. J. (1999) Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J. Neurosci. Res. 57, 86 94.
7. Choi W. S., Eom D. S., Han B. S. et al. (2004) Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8- and -9-mediated apoptotic pathways in dopaminergic neurons. J. Biol. Chem. 279, 20451 20460.
8. Cobb M. H. Goldsmith E. J. (1995) How MAP kinases are regulated. J. Biol. Chem. 270, 14843 14846.
9. Cohen G. Heikkila R. E. (1974) The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J. Biol. Chem. 249, 2447 2452.
10. Dexter D. T., Carter C. J., Wells F. R., Javoy-Agid F., Agid Y., Lees A., Jenner P. Marsden C. D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381 389.
11. Ferrer I., Blanco R., Carmona M., Puig B., Barrachina M., Gomez C. Ambrosio S. (2001) Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and dementia with Lewy bodies. J. Neural Transm. 108, 1383 1396.
12. Floor E. Wetzel M. G. (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 70, 268 275.
13. Glinka Y. Y. Youdim M. B. (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur. J. Pharmacol. 292, 329 332.
14. Gomez-Lazaro M., Galindo M. F., Concannon C. G., Segura M. F., Fernandez-Gomez F. J., Llecha N., Comella J. X., Prehn J. H. Jordan J. (2008) 6-Hydroxydopamine activates the mitochondrial apoptosis pathway through p38 MAPK-mediated, p53-independent activation of Bax and PUMA. J. Neurochem. 104, 1599 1612.
15. Graham D. G. (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633 643.
16. Guerin M., Huntley M. E. Olaizola M. (2003) Haematococcus astaxanthin: applications for human health and nutrition. Trends Biotechnol. 21, 210 216.
17. Guo S., Bezard E. Zhao B. (2005) Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway. Free Radic. Biol. Med. 39, 682 695.
18. Halvorsen E. M., Dennis J., Keeney P., Sturgill T. W., Tuttle J. B. Bennett J. B. Jr. (2002) Methylpyridinium [MPP(+)]- and nerve growth factor-induced changes in pro- and anti-apoptotic signaling pathways in SH-SY5Y neuroblastoma cells. Brain Res. 952, 98 110.
19. Harada C., Nakamura K., Namekata K. et al. (2006) Role of apoptosis signal-regulating kinase 1 in stress-induced neural cell apoptosis in vivo. Am. J. Pathol. 168, 261 269.
20. Ikeda Y., Murakami A. Ohigashi H. (2005) Ursolic acid promotes the release of macrophage migration inhibitory factor via ERK2 activation in resting mouse macrophages. Biochem. Pharmacol. 70, 1497 1505.
21. Jameson G. N. L. Linert W. (1999) 6-hydroxydopamin, dopamine, and ferritin: a cycle of reactions sustaining Parkinson's disease, in Free Radicals in Brain Pathophysiology (Poli G., Cadenas E. Packer L., eds), pp. 247 272. Marcel Dekker, Inc., New York.
22. Jenner P. (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13 (Suppl. 1 24 34.
23. Jenner P. Olanow C. W. (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47, 161 170.
24. Junn E. Mouradian M. M. (2001) Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases. J. Neurochem. 78, 374 383.
25. Krinsky N. I. Johnson E. J. (2005) Carotenoid actions and their relation to health and disease. Mol. Aspects Med. 26, 459 516.
26. Kumar R., Agarwal A. K. Seth P. K. (1995) Free radical-generated neurotoxicity of 6-hydroxydopamine. J. Neurochem. 64, 1703 1707.
27. Kurashige M., Okimasu E., Inoue M. Utsumi K. (1990) Inhibition of oxidative injury of biological membranes by astaxanthin. Physiol. Chem. Phys. Med. NMR 22, 27 38.
28. Kuwabara T. Imajoh-Ohmi S. (2004) LPS-induced apoptosis is dependent upon mitochondrial dysfunction. Apoptosis 9, 467 474.
29. Lee C. S., Sauer H. Bjorklund A. (1996) Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 72, 641 653.
30. Lee S. J., Bai S. K., Lee K. S. et al. (2003) Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol. Cells 16, 97 105.
31. Lee H. J., Noh Y. H., Lee D. Y., Kim Y. S., Kim K. Y., Chung Y. H., Lee W. B. Kim S. S. (2005) Baicalein attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. Eur. J. Cell Biol. 84, 897 905.
32. Levites Y., Youdim M. B., Maor G. Mandel S. (2002) Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem. Pharmacol. 63, 21 29.
33. Lewis T. S., Shapiro P. S. Ahn N. G. (1998) Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74, 49 139.
34. Lo Bianco C., Schneider B. L., Bauer M., Sajadi A., Brice A., Iwatsubo T. Aebischer P. (2004) Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl Acad. Sci. USA 101, 17510 17515.
35. Lotharius J. Brundin P. (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3, 932 942.
36. Lotharius J., Dugan L. L. O'Malley K. L. (1999) Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci. 19, 1284 1293.
37. Luo Y., Umegaki H., Wang X., Abe R. Roth G. S. (1998) Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol. Chem. 273, 3756 3764.
38. Manabe E., Handa O., Naito Y. et al. (2008) Astaxanthin protects mesangial cells from hyperglycemia-induced oxidative signaling. J. Cell. Biochem. 103, 1925 1937.
39. Miki W., Yamaguchi K. Konosu S. (1982) Comparison of carotenoids in the ovaries of marine fish and shellfish. Comp. Biochem. Physiol. B 71, 7 11.
40. Nie G., Cao Y. Zhao B. (2002) Protective effects of green tea polyphenols and their major component, (-)-epigallocatechin-3-gallate (EGCG), on 6-hydroxydopamine-induced apoptosis in PC12 cells. Redox Rep. 7, 171 177.
41. Ouyang M. Shen X. (2006) Critical role of ASK1 in the 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J. Neurochem. 97, 234 244.
42. Pan J., Wang G., Yang H. Q., Hong Z., Xiao Q., Ren R. J., Zhou H. Y., Bai L. Chen S. D. (2007) K252a prevents nigral dopaminergic cell death induced by 6-hydroxydopamine through inhibition of both mixed-lineage kinase 3/c-Jun NH2-terminal kinase 3 (JNK3) and apoptosis-inducing kinase 1/JNK3 signaling pathways. Mol. Pharmacol. 72, 1607 1618.
43. Przedborski S. Jackson-Lewis V. (1998) Mechanisms of MPTP toxicity. Mov. Disord. 13 (Suppl. 1 35 38.
44. de Rijk M. C., Breteler M. M., den Breeijen J. H., Launer L. J., Grobbee D. E., van der Meche F. G. Hofman A. (1997) Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch. Neurol. 54, 762 765.
45. Robinson M. J. Cobb M. H. (1997) Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9, 180 186.
46. Saner A. Thoenen H. (1971) Model experiments on the molecular mechanism of action of 6-hydroxydopamine. Mol. Pharmacol. 7, 147 154.
47. Saporito M. S., Brown E. M., Miller M. S. Carswell S. (1999) CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. 288, 421 427.
48. Sauer H. Oertel W. H. (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59, 401 415.
49. Schober A. (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 318, 215 224.
50. Sherer T. B., Betarbet R. Greenamyre J. T. (2001) Pathogenesis of Parkinson's disease. Curr. Opin. Investig. Drugs 2, 657 662.
51. Shimoke K. Kudo M. (2002) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine has a transient proliferative effect on PC12h cells and nerve growth factor additively promotes this effect: possible involvement of distinct mechanisms of activation of MAP kinase family proteins. Brain Res. Dev. Brain Res. 133, 105 114.
52. Shinkai T., Zhang L., Mathias S. A. Roth G. S. (1997) Dopamine induces apoptosis in cultured rat striatal neurons; possible mechanism of D2-dopamine receptor neuron loss during aging. J. Neurosci. Res. 47, 393 399.
53. Suganuma H., Hirano T., Arimoto Y. Inakuma T. (2002) Effect of tomato intake on striatal monoamine level in a mouse model of experimental Parkinson's disease. J. Nutr. Sci. Vitaminol. (Tokyo) 48, 251 254.
54. Tian L. L., Zhou Z., Zhang Q., Sun Y. N., Li C. R., Cheng C. H., Zhong Z. Y. Wang S. Q. (2007) Protective effect of (+/-) isoborneol against 6-OHDA-induced apoptosis in SH-SY5Y cells. Cell. Physiol. Biochem. 20, 1019 1032.
55. Tiffany-Castiglioni E. Perez-Polo J. R. (1981) Stimulation of resistance to 6-hydroxydopamine in a human neuroblastoma cell line by nerve growth factor. Neurosci. Lett. 26, 157 161.
56. Tso M. O. M. Lam T. T. (1996) Method of Retarding and Ameliorating Central Nervous System and Eye Damage. US Patent #5527533.
57. Walkinshaw G. Waters C. M. (1994) Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis. Neuroscience 63, 975 987.
58. Xia X. G., Harding T., Weller M., Bieneman A., Uney J. B. Schulz J. B. (2001) Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 10433 10438.
59. Zou H., Li Y., Liu X. Wang X. (1999) An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274, 11549 11556.